Sun Pharma Advanced Research (SPARC) has reported results for first quarter ended June 30, 2021.
The company has reported net loss at Rs 61.37 crore for the quarter under review as compared to net profit of Rs 56.69 crore for the same quarter in the previous year. Total income of the company decreased by 87.75% at Rs 22.79 crore for Q1FY22 as compared Rs 186.11 crore for the corresponding quarter previous year.
SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.
| Company Name | CMP |
|---|---|
| Syngene Internation. | 435.70 |
| Indegene | 486.80 |
| CMS Info Systems | 318.00 |
| JITF Infralogistics | 338.00 |
| Sagility | 42.95 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: